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depends on the predominance of axial (sacroiliitis, 
spondylitis) or peripheral (arthritis, enthesitis, 
dactylitis) symptoms. While joint involvement in 
peripheral SpA is related to more expressed pain 
and stiffness of peripheral tissues, axial disease 
INTRODUCTION Spondyloarthritis (SpA) is a het‑
erogeneous group of diseases that can be classified 
as axial or peripheral SpA, according to the As‑
sessment of SpondyloArthritis International So‑
ciety classification criteria.1-4 The classification 
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ABSTRACT
INTRODUCTION A different clinical course and pattern of skeletal involvement in peripheral and axial 
spondyloarthritis (SpA) suggests a distinct pathophysiology of these 2 phenotypic manifestations of 
SpA. Monocytes, as part of the innate immune system, seem to play an important role in the pathogenesis 
of SpA, but the exact inflammatory pathways remain to be elucidated. Regulatory T lymphocytes (Treg) 
and Th17 lymphocytes are also known to influence proinflammatory and anti ‑inflammatory reactions.
OBJECTIVES The aim of our study was to compare the absolute numbers of monocyte subpopulations, Treg, 
and Th17 lymphocytes with clinical measures of disease activity in patients with peripheral and axial SpA.
PATIENTS AND METHODS We enrolled 21 patients with peripheral SpA and 27 patients with axial SpA 
diagnosed according to the Assessment of SpondyloArthritis International Society classification criteria, 
as well as 23 healthy controls. Patients were under 45 years, naïve to synthetic and biological disease‑
‑modifying antirheumatic drugs and without the administration of systemic glucocorticoids. The absolute 
numbers of classical, intermediate, nonclassical monocytes, Treg, and Th 17 in peripheral blood were analyzed. 
Disease activity was assessed using the Ankylosing Spondylitis Disease Activity Score (ASDAS‑CRP), 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Disease Activity Score 28 (DAS28).
RESULTS In patients with SpA, the number of circulating nonclassical monocytes was decreased in 
comparison with controls. Only in the peripheral SpA group, a significant negative correlation was found 
between the concentration of nonclassical monocytes and DAS28 and the number of swollen joints. 
The 3 groups did not differ in terms of the concentrations of classical or intermediate monocytes and 
Treg or Th17 lymphocytes.
CONCLUSIONS Nonclassical monocytes may play a role in induction and perpetuation of peripheral joint 
inflammation, at least in peripheral SpA, as cells infiltrating the synovium.
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clinical manifestations and elevated inflamma‑
tory parameters localized in periarticular tis‑
sue.6,7 Migration of this subpopulation to synovi‑
al tissue is mediated by a fractalkine interaction 
with CX3CR1.16 Moreover, dendritic cells origi‑
nating from migrating monocytes seem to partic‑
ipate in osteogenesis and inflammation ‑mediated 
destruction of bone tissue in inflammatory ar‑
thritis.17 Patients with RA present a significantly 
higher percentage of CD16+ monocytes, as com‑
pared with healthy subjects, with a positive cor‑
relation between the Disease Activity Score 28 
(DAS28) and ultrasound composite score US7.18 
Patients with PsA and psoriasis have a higher per‑
centage of circulating nonclassical CD14+CD16++ 
cells than healthy controls.9 On the contrary, in 
patients with axial SpA and ankylosing spondyli‑
tis (AS), the percentage of intermediate and non‑
classical subsets was reduced, as compared with 
healthy controls.19,20 In a recent study by Per‑
pétuo et al,21 a lower frequency of nonclassical 
monocytes was reported in AS, but there were no 
differences in classical and intermediate mono‑
cytes. It was also suggested that monocytes fa‑
vor maintenance of inflammation in periarticu‑
lar tissues in patients with AS.22
Previous studies suggested the involvement of 
particular monocyte subsets in the pathogenesis 
of inflammation in SpA (TABLE 1), although the re‑
sults were contradictory. To our best knowledge, 
so far there have been no data linking the abso‑
lute numbers of monocyte subpopulations in 
the context of Treg and Th17 lymphocytes with 
clinical measures of joint inflammation in pe‑
ripheral and axial SpA.
PATIENTS AND METHODS Patients and con-
trols We enrolled 27 patients with axial SpA 
and 21 patients with peripheral SpA, diagnosed 
according to the Assessment of SpondyloArthri‑
tis International Society classification criteria,14 
as well as 23 healthy controls. Eligible patients 
were younger than 45 years of age, were naive to 
treatment with synthetic or biological disease‑
‑modifying antirheumatic drugs, and were not 
using systemic glucocorticoids. Patients provided 
a signed informed consent and the study proto‑
col was approved by a local bioethics committee.
Cytometric analysis Whole peripheral blood sam‑
ples from patients with SpA and from healthy 
controls were drawn to EDTA ‑containing tubes 
(Vacutainer System®; Becton Dickinson Biosci‑
ences, San Jose, California, United States). The 
monocyte subsets were analyzed as previously de‑
scribed by our group and others.23,24 Briefly, blood 
samples were washed with 0.9% sodium chloride 
in polypropylene round ‑bottom tubes (BD Biosci‑
ences) and centrifuged (1000 × g). Then, cell sus‑
pension was placed in the TruCOUNTTM tubes 
(BD Biosciences) along with monoclonal antibod‑
ies (mAbs): anti –CD45 ‑APC, anti –HLA ‑DR ‑PerCP, 
anti –CD14 ‑FITC, and anti –CD16 ‑PE (BD Bio‑
sciences), and incubated for 30 minutes at 4°C. 
leads to more pronounced new bone formation 
and ankylosis of the spine and sacroiliac joints. 
Differences in the clinical course and pattern of 
skeleton and joint involvement suggest a dis‑
tinct pathomechanism of these 2 subsets of SpA, 
but the exact inflammatory and bone remodel‑
ing mechanisms, especially in early disease, re‑
main unknown.
Monocytes, as part of the innate immune sys‑
tem, seem to play an important role in the patho‑
genesis of SpA.5-7 Under physiological and inflam‑
matory conditions, circulating monocytes, upon 
leaving blood vessels, may transform into tissue 
macrophages, antigen‑presenting cells, and os‑
teoclasts. Monocytes are a heterogeneous cell 
population, divided at least into 3 subsets: classi‑
cal (CD14++CD16–), intermediate (CD14++CD16+), 
and nonclassical (CD14+CD16++) cells.8 The latter 
2 subsets, collectively called CD16+ monocytes, 
are considered to possess pro inflammatory activi‑
ties. Moreover, several studies revealed the role of 
CD16+ monocytes as precursors of osteoclasts in 
psoriatic arthritis (PsA)9 or promotors of the ex‑
pansion of the Th17 lymphocytes in rheumatoid 
arthritis (RA).10 However, each monocyte subset 
may express distinct, sometimes contradictory 
functions in inflammation.8 
Nonclassical monocytes form 5% to 15% of cir‑
culating monocyte pool and, in comparison with 
the classical subtype, are considered as more ma‑
ture. They also have a higher expression of hu‑
man leukocyte antigens (HLA) class II (mostly 
HLA ‑DR). After stimulation with bacterial prod‑
ucts (ie, lipopolysaccharide), they express and se‑
crete large amounts of pro inflammatory cyto‑
kines, for example, tumor necrosis factor (TNF) 
and interleukins (IL) IL ‑12 and IL ‑1, and almost 
no anti ‑inflammatory IL ‑10.11 They also exhibit 
a lower capacity to phagocytosis but higher abil‑
ity to present antigens, that is why they seem to 
functionally resemble dendritic cells.12 Due to 
the high expression of the integrins of the β2 fam‑
ily (CD11a, CD11c, and CD18), very late antigen  4 
(VLA ‑4), fractalkine receptor CX3CR1, and che‑
mokine receptor CCR5, they tend to strongly ad‑
here to the endothelium, which may lead to en‑
hanced transmigration to inflammatory lesions.
By contrast, classical monocytes have been 
suggested to have a potential to produce anti‑
‑inflammatory IL ‑10 and exhibit a relatively high 
phagocytic activity.11 Intermediate monocytes are 
suggested to be the primary producers of soluble 
CD18 integrins,13 which inhibit leukocyte migra‑
tion by antagonistic binding to intercellular ad‑
hesion molecule 1 (ICAM ‑1) in the endothelium 
and synovium.14 They form a transient pool of 
circulating monocytes that functionally resem‑
ble nonclassical cells.15
Several studies suggested an important role 
of CD16+ monocytes (intermediate and nonclas‑
sical) in the pathogenesis of different inflamma‑
tory rheumatic diseases. In patients with RA, 
an increased monocyte count (especially the 
CD14+CD16++ subpopulation) correlates with 
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beginning of the culture. Next, the cells were 
harvested and stained with the following mAbs: 
anti –CD4 ‑PerCP ‑Cy5.5, anti–IL ‑17A ‑PE, and anti– 
–FoxP3 ‑Alexa Fluor 647, using the human Th17/Treg 
Phenotyping Kit (BD Pharmingen, BD Biosci‑
ences) according to the manufacturer’s instruc‑
tions. The samples were analyzed in the FACS‑
Canto flow cytometer using the FACSDiva soft‑
ware. The absolute numbers of Treg and Th17 cells 
were calculated on the basis of their percent‑
age of CD4+ T cells and the absolute number of 
CD3+/CD4+ T cells.
Statistical analysis Database management and 
analysis were performed using SAS 9.2 (SAS In‑
stitute Inc., Cary, North Carolina, United States) 
and GraphPad PRISM (GraphPad Software Inc., 
San Diego, California, United States) software 
packages. The variables following a nonnormal 
distribution were presented as medians (IQR), 
and those that were normally distributed, as 
means (SD). The nonnormally distributed data 
were analyzed using nonparametric tests (Wil‑
coxon rank sum test for comparison of unpaired 
continuous data, and Spearman rank correlation 
analysis for correlation analysis). The means of 
normally distributed variables were compared 
using the t test. The proportions were compared 
using the χ2 test. All P values were 2‑tailed, and 
5% was considered as the threshold for signifi‑
cance. For the analysis of the cell subsets, we used 
The samples were then treated with FACS Lysing 
Solution (BD Biosciences) until erythrocyte ly‑
sis and immediately processed in the FACSCan‑
to flow cytometer (Becton Dickinson Immuno‑
cytometry Systems, BD Biosciences) along with 
10 000 of beads per tube, and then analyzed with 
FACSDiva Software (BD Biosciences). The abso‑
lute numbers of monocytes were calculated with 
reference to the bead count.
Peripheral blood samples were also incubated 
in the TruCOUNTTM tubes with anti –CD3 ‑FITC 
and anti –CD4 ‑PE (BD Simultest, BD Bioscienc‑
es) mAbs, followed by erythrocyte lysis and anal‑
ysis on a FACSCanto flow cytometer, in order 
to count the absolute numbers of CD3+CD4+ 
T lymphocytes.
For Treg and Th17 lymphocyte analysis, periph‑
eral blood mononuclear cells (PBMC) were iso‑
lated from EDTA ‑treated peripheral blood sam‑
ples by standard Ficoll ‑Paque density gradient 
centrifugation (Pharmacia, Uppsala, Sweden). 
PBMC samples were suspended in RPMI 1640 
medium supplemented with 10% fetal calf se‑
rum (Biochrom, Berlin, Germany) and strepto‑
mycin (50 µg/ml, Gibco BRL, Karlsruhe, Germa‑
ny). Then, PBMC samples were stimulated with 
PMA (phorbol ‑12 ‑myristate ‑13 ‑acetate) and ion‑
omycin (at 50 ng/ml and 1 μg/ml, respectively) 
for 5 hours at 37°C. To inhibit cytokine secre‑
tion, monensin (2 µM, GolgiStop Protein Trans‑
port Inhibitor, BD Biosciences) was added at the 
TABLE 1 Summary of studies on the role of monocyte subpopulations in patients with spondyloarthritis
Diagnosis No. of 
patients
Levels of Mo subsets 
vs control, %
Other findings Hypothesis References
AS 30 ↓ Nonclassical Mo, no 
difference in classical/
intermediate Mo
↓ CD51/CD61, ↓ RANK in classical Mo,
↑ CD51/CD61, ↑ RANK in intermediate Mo,
↑ CD62L in nonclassical Mo
↓ OC formation and adhesion 
to bone matrix (↓  bone 
resorption)
Perpétuo  
et al41
AS 13 No difference ↑ CD62L in classical Mo at baseline, 
↑ CD62L in all Mo subtypes after 6 ‑month 
therapy with TNF inhibitors,
↓ CCR2 on intermediate Mo after TNF 
inhibitor therapy
TNF–inhibitor ‑treated patients 
have an early increase of 
bone resorption by TNF 
inhibitors, thus preventing 
osteoproliferation
Perpétuo  
et al21
Axial SpA 57 ↑ Classical Mo,
↓ Nonclassical and 
intermediate Mo
↑ Mo producing IL ‑1β and IL ‑1ra 
spontaneously,
↑ Mo producing IL‑1β after MDP 
stimulation
In vivo Mo pre activation Conrad  
et al19
AS 47 ↑ Classical Mo (%, n)
↓ Nonclassical Mo (%, n)
↑ CD11b on all Mo subtypes correlated 
with disease activity,
↑ IL ‑6 correlated with number of classical Mo
↑ Leukocyte –endothelial 
interaction
Surdacki  
et al20
AS;
Non–
radiographic 
axial SpA
47;
37
– ↓ sCD18 correlated with disease activity, 
sCD18 shed primarily from intermediate 
Mo
Insufficient shedding of sCD18 
from Mo do not counter‑ 
balance the capture of 
ICAM ‑1, ↑ migration of 
leukocytes to entheses/
joints
Kragstrup 
et al13
PsA 29 ↑ Nonclassical and 
intermediate Mo (%)
↑ CD16 expression correlated with ↑ bone 
erosion activity
CD16 as a potential marker of 
OC precursors
Chiu et al9
Abbreviations: AS, ankylosing spondylitis; CCR2, chemokine receptor binding MCP ‑1, promoting OC differentiation; CD11b, β2 ‑integrin, an endothelial 
ligand for monocytes; CD16, low‑affinity immunoglobulin (Ig) G Fcγ receptor (FcγRIII); CD51/CD61 (αvβ3 integrin), important for monocytes and OC 
adhesion to the bone matrix; CD62L, cell adhesion molecule also known as L ‑selectin; ICAM ‑1, intercellular adhesion molecule 1; IL ‑1β, interleukin 1β; 
IL ‑1ra, interleukin‑1 receptor antagonist; IL‑6, interleukin 6; MDP, muramyl dipeptide; Mo, monocytes; OC, osteoclasts; PsA, psoriatic arthritis; sCD18, 
soluble CD18, family of β2‑integrins, binding to ICAM ‑1; SpA, spondyloarthritis; RANK, receptor activator of nuclear factor κB; TNF, tumor necrosis factor
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of nonclassical monocytes between the 2 groups 
of patients (P = 0.51) (FIGURE 1A).
There were no differences between the groups 
in terms of the intermediate and classical mono‑
cyte counts (FIGURE 1B and 1C, respectively). The 
groups did not differ in the absolute number of 
circulating Treg and Th17 lymphocytes (FIGURE 2A and 
2B, respectively).
Monocyte subpopulations and disease activity 
In the  peripheral SpA group, there were no 
correlations between the  absolute num‑
bers of the 3 monocyte subpopulations and 
the ASDAS ‑CRP score, BASDAI score, CRP level, 
and ESR value (all P >0.27). Similar findings were 
observed for the axial SpA group (all P >0.29). In 
patients with peripheral SpA, we found a signifi‑
cant negative correlation between the concentra‑
tion of nonclassical monocytes and the DAS28 
(r = –0.59, P = 0.02) and the number of swollen 
joints (r = –0.64, P = 0.004). We found no cor‑
relations between the indicators of the clinical 
disease activity and Treg or Th17 levels in either 
group of patients. Moreover, in the entire study 
group and the subgroups, we did not observe 
correlations between the number of monocyte 
subpopulations, Treg, or Th17 and the duration 
of SpA (P >0.51 for the entire group; P >0.11 for 
the subgroup analyses).
DISCUSSION The principal findings of our study 
based on the measurement of the absolute num‑
bers of circulating cell subsets are as follows: 1) 
the numbers of nonclassical monocytes are sig‑
nificantly lower in both peripheral and axial SpA 
as compared with healthy controls; 2) there was 
no disease ‑type (peripheral and axial SpA) spe‑
cific association between the ASDAS ‑CRP score, 
BASDAI score, CRP levels, and ESR and monocyte 
subpopulation levels; 3) there is a strong negative 
correlation between the number of nonclassical 
monocytes and the clinical indicators of periph‑
eral joint involvement (DAS28 and the number 
of swollen joints) in peripheral SpA; and finally 
4) there is no significant association between Treg 
or Th17 concentrations and clinical measures of 
disease activity either in peripheral or axial SpA. 
Taking these data together, we assume that non‑
classical monocytes may be involved in the patho‑
genesis of peripheral SpA.
Our findings in patients with SpA are in con‑
trast to the results of Amoruso et al18 who re‑
ported that patients with RA presented a sig‑
nificantly higher percentage of CD16+ mono‑
cytes compared with healthy controls. However, 
Amoruso et al18 analyzed monocyte proportions 
rather than the absolute numbers. The incom‑
patibility of methodology makes it impossible 
to draw conclusions on the similarities or dif‑
ferences of the involvement of monocyte sub‑
sets in the pathology of RA and peripheral SpA 
in the context of the DAS28 score. Additionally, 
in our patients with axial SpA, we found no as‑
sociation between the ASDAS‑CRP or BASDAI 
the absolute numbers. In the diagrammatic rep‑
resentations, single data points were omitted (1 
in FIGURE 1, and 2 and 3 in FIGURE 2A and 2B, respec‑
tively); however, they contributed to the present‑
ed medians and IQRs.
RESULTS Study group characteristics The base‑
line characteristics of patients with axial and pe‑
ripheral SpA are shown in TABLE 2. Healthy con‑
trols were recruited to match the mean (SD) age 
(35.1 [5.4] years) and sex distribution (52.4% 
males) of both groups. Overall, the mean (SD) 
age did not differ between the axial and peripher‑
al SpA groups. The groups did not differ in terms 
of the median (IQR) disease duration, C‑reac‑
tive protein (CRP) levels, and erythrocyte sedi‑
mentation rate (ESR). We found significant dif‑
ferences between peripheral and axial SpA in 
the BASDAI but not in the ASDAS ‑CRP score. 
By definition, the DAS28 was calculated for pe‑
ripheral disease only.
Monocyte subpopulation, Treg, and Th17 counts 
The absolute number of nonclassical monocytes 
was the highest in the control group and was dif‑
ferent from that in patients with peripheral SpA 
(P = 0.008) and those with axial SpA (P = 0.02). 
There was no difference in the absolute numbers 
TABLE 2 Baseline characteristics of patients with spondyloarthritis
Parameter Axial SpA Peripheral SpA P value
No. (%) of patients 27 (56.25) 21 (43.75) 0.39
Age, y, mean (SD) 32.9 (7.7) 35.1 (5.4) 0.31
Male sex, % 59.5 52.4 0.63
HLA‑B27 positive, % 91.7 53.8 0.008
Duration of symptoms, 
median (IQR), y
7.5 (5–10) 3.0 (2–14) 0.08
IBP, % 88.5 36.8 0.0003
Arthritis, % 15.5 84.2 <0.0001
Enthesitis, % 26.9 95.8 0.02
Dactylitis, % 3.8 89.5 <0.0001
Uveitis, % 26.9 0 0.01
Psoriasis, % 4.0 57.9 <0.0001
CRP, median (IQR), mg/l 8.8 (2.4–12.9) 7.4 (2.6–13.1) 0.71
ESR, median (IQR), mm/h 22.5 (15.0–31.0) 25.0 (17.0–42.0) 0.35
BASDAI (0–10 scale), 
median (IQR)
2.1 (0.8–4.4) 4.0 (2.3–6.4) 0.02
ASDAS ‑CRP, median 
(IQR)
2.1 (1.6–3.1) 2.7 (2.1–3.6) 0.09
DAS28, median (IQR) NA 4.0 (3.0–4.4) –
Sacroiliitis on X ‑ray 
(modified New York 
criteria), n (%)
18 (66.7) 2 (9.5) <0.0001
Extra‑articular and peripheral sings percentage difference between the groups are 
based on the χ2 test.
Abbreviations: ASDAS ‑CRP, Ankylosing Spondylitis Disease Activity Score; BASDAI, 
Bath Ankylosing Spondylitis Disease Activity Index; CRP, C ‑reactive protein; ESR, 
erythrocyte sedimentation rate; IBP, inflammatory back pain; NA, not applicable; 
HLA B27, human leucocyte antigen B27; others, see TABLE 1
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FIGURE 1  
Concentrations of 
nonclassical 
(CD14+CD16++; A), 
intermediate 
(CD14++CD16+; B), and 
classical monocytes 
(CD14++CD16–; C) in 
patients with axial and 
peripheral 
spondyloarthritis (SpA), 
and healthy controls. 
Individual data points, 
medians, and interquartile 
ranges are shown.
 C
D1
4+
16
+
+
, c
el
ls
/μ
l
0
50
Axial SpA Peripheral SpA Control
100
150 P = 0.02
P = 0.008
CD
14
+
+
CD
16
+
, c
el
ls
/μ
l
 C
D1
4+
+
CD
16
– , 
ce
lls
/μ
l
0
50
Axial SpA Peripheral SpA Control
100
150
0
500
Axial SpA Peripheral SpA Control
1000
1500
2000
A
C
B
ORIGINAL ARTICLE Nonclassical monocytes in peripheral spondyloarthritis 851
colony‑stimulating factor concentration in the 
sera of patients with SpA was significantly higher 
than in the control group, with no difference be‑
tween axial and peripheral SpA (unpublished data), 
lends support to the latter hypothesis. Moreover, 
in our study, we found no differences in the num‑
ber of intermediate monocytes, suggesting pro‑
nounced transmigration of nonclassical but not of 
intermediate cells. Additionally, the nonclassical 
monocytes appear to be accumulated in the mar‑
ginal pool inside the vessels, where they are pref‑
erentially located because of a higher expression 
of adhesion molecules such as CD11d and VLA‑
4.26 The third hypothesis explaining the dimin‑
ished number of nonclassical monocytes is their 
rapid destruction and elimination from the cir‑
culation, that is, in the spleen. However, it seems 
less probable in the context of a significant nega‑
tive correlation between the low number of non‑
classical monocytes and clinical manifestations of 
clinical activity indicators and the numbers of 
monocyte subsets. However, this finding does 
not preclude the possibility that the nonclassi‑
cal monocytes are involved in the pathogenesis 
of axial SpA and may indicate that these clini‑
cal indicators are not sensitive enough with re‑
spect to monocyte ‑induced peripheral inflam‑
matory changes, or inflammation might not be 
the leading pathology in axial SpA, dependent 
on nonclassical monocytes.
The  most probable hypotheses to explain 
the low level of nonclassical monocytes in our 
patients are: 1) inhibition of their development, 
or 2) migration of monocytes from blood to pe‑
ripheral tissues, that is, synovium of the joints. It 
was suggested that the essential role in the pro‑
motion of differentiation of classical monocytes 
to intermediate and nonclassical ones is mediat‑
ed by macrophage colony‑stimulating factor.25 
Our preliminary observation that the macrophage 
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FIGURE 2  
Concentrations of 
regulatory T lymphocytes 
(CD4+Foxp3+; A) and 
Th17 lymphocytes 
(CD4+Th17A+; B) in 
patients with axial and 
peripheral 
spondyloarthritis (SpA), 
and healthy controls. 
Individual data points, 
medians, and interquartile 
ranges are shown.
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classification criteria.32 However, in contrast to 
the above study, our analysis was based on the 
absolute numbers of the respective cell types 
rather than on the percentages, which to some 
extent may explain the discrepancy. Additional‑
ly, there was no difference in the numbers of re‑
spective cells between patients with peripheral 
SpA with and without psoriasis (data not shown).
A clinical implication of our study is that 
blocking transmigration of nonclassical mono‑
cytes into peripheral joints could possibly be 
used in the treatment of synovitis, that is, with 
anti ‑CCR5 monoclonal antibodies. The clinical 
efficacy of glucocorticoids in peripheral arthri‑
tis could be explained by the depletion of non‑
classical monocytes.33,34 This is consistent with 
the improvement of clinical symptoms in pa‑
tients with psoriasis and PsA after depletion of 
CD14+16++ proinflammatory monocytes by ad‑
sorptive granulocyte and monocyte apheresis.35,36
In our study, we did not find any significant 
changes in the numbers of Treg and Th17 between 
any studied group and no correlations of the cell 
numbers with clinical disease activity measure‑
ments. However, some animal models and in vi‑
tro studies suggested a dysregulation between 
anti ‑inflammatory Treg lymphocytes and proin‑
flammatory Th17 lymphocytes, 37-39 as well as bi‑
lateral interactions between Treg and Th17 lym‑
phocytes in these patients.40 However, these data 
must be confirmed by further investigations.
Our study has some limitations. First, we an‑
alyzed a relatively small number of patients, and 
the studied populations were heterogeneous in 
terms of the percentage of extra ‑articular signs 
and symptom duration. Second, our hypothesis 
of the enhanced migration of monocytes from 
blood to the site of inflammation is based on the 
number of monocytes in the peripheral blood and 
must be confirmed in an animal model setting. 
However, the strength of our study is the fact 
that patients were under 45 years of age and 
were treatment‑naive as any therapy may have 
influenced the levels of circulating immune cells.
In conclusion, our results suggest the impor‑
tant role of nonclassical monocytes in the ear‑
ly form of peripheral SpA, as these cells may in‑
filtrate the synovium and play a role in the in‑
duction and maintenance of peripheral joint 
inflammation.
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peripheral SpA and DAS28. Also, we did not find 
an increase in the serum concentration of circulat‑
ing extracellular vesicles – membrane fragments, 
which should accompany cellular activation and 
may reflect a massive apoptosis of monocytes27 
(data not shown).
To date, there have been limited histopatho‑
logical data from human studies in early forms 
of these diseases. In a study by Paramarta et al,28 
the severity of synovial inflammation as assessed 
by immunohistochemistry was similar in early RA 
and peripheral SpA, but the number of CD163 
macrophages originating from activated mono‑
cytes was significantly higher in the synovial sub‑
lining of joints in patients with peripheral SpA. In 
patients with different forms of arthritis, signif‑
icantly higher percentages of CCR5 ‑expressing 
mononuclear cells in the synovial fluid compared 
with peripheral blood (51% vs 7.8%, respectively) 
was reported by Mack et al,29 supporting the hy‑
pothesis of their transmigration or upregulation 
of CCR5 expression on the cells already present 
in the effusion.29 In fact, among monocyte sub‑
populations in peripheral blood, mainly nonclas‑
sical monocytes express CCR5, and as such they 
are predisposed to migration from blood to the 
sites of peripheral inflammation.30 
All these observations may support the hypoth‑
eses of a more pronounced migration of mono‑
cytes into the synovium in peripheral SpA. It is 
also consistent with the hypothesis proposed by 
Kragstrup et al13 that the insufficient upregulation 
of CD18 shedding from intermediate monocytes 
in patients with HLAB27+ SpA facilitates leukocyte 
migration to the entheses and joints and results in 
aggravating disease activity. Also, in a recent study 
on lupus nephritis, Garcia et al31 reported that pa‑
tients with more severe forms of the disease had 
a higher grade of CD14+CD16++ cell infiltration in 
the kidneys and a lower peripheral blood level of 
nonclassical monocytes. Their observation may 
reflect the monocyte migration into renal tissue,  
which is in line with our hypothesis that in pe‑
ripheral SpA nonclassical monocytes migrate to 
the synovium of peripheral joints, inducing and 
maintaining local inflammation. However, inde‑
pendent ex vivo experiments and animal mod‑
el studies are needed to confirm these findings.
Another important aspect of our study is that 
contrary to the results for synovitis, there was 
no difference in the concentration of monocyte 
subsets according to the presence or absence 
of enthesitis, dactylitis, or inflammatory spi‑
nal and lower back pain. A possible explanation 
of this finding is that the process of migration 
of monocytes is more pronounced in active sy‑
novitis than in other peripheral or axial symp‑
toms. However, this requires further confirma‑
tion, possibly based on a histological assessment 
of synovial biopsies.
Our results are not consistent with the find‑
ing of the elevated percentage of CD16+ mono‑
cytes in patients with PsA,9 as certain percent‑
age of peripheral SpA may fit in the PsA CASPAR 
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